Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Rodrigo R. Munhoz"'
Autor:
Carlos Diego H. Lopes, Marcello M. Queiroz, Luana A.F. Sampaio, André Perina, Eduardo Akaishi, Frederico Teixeira, Fábio de O. Ferreira, Samir A. Hanna, João Luís F. da Silva, Luiz Guilherme C.A. De Lima, Claudia Regina G.C.M. de Oliveira, Rodrigo R. Munhoz
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSETo investigate the discordance in sarcoma diagnoses between nonspecialized institutions following revision by dedicated sarcoma pathologists at a reference center in Brazil and the relevance of molecular pathology in this context.METHODSWe con
Externí odkaz:
https://doaj.org/article/0074bc4ef8cb4bfe9650762e64436c55
Autor:
Cesar M. Costa, Luiza L. Gadotti, Maria C. Seiwald, Alessandra C. R. Salgues, Fernando Ganem, Ellen C. T. Nascimento, David E. Uip, Celso Arrais-Rodrigues, Rodrigo R. Munhoz
Publikováno v:
Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-5 (2021)
Abstract Background Hemophagocytic lymphohistiocytosis is a rare, potentially fatal syndrome of immune hyperactivation. Here we describe a ganglionar tuberculosis evolving to hemophagocytic lymphohistiocytosis following adjuvant immunotherapy in a me
Externí odkaz:
https://doaj.org/article/d03aa67bf7b54796a20eaae52302b281
Autor:
Leandro J. C. Oliveira, Aline B. L. Gongora, Felipe G. Barbosa, Carlos H. dos Anjos, Rodrigo R. Munhoz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Currently, there is no established standard of care for patients with metastatic CSCC. Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade. This case illustrates a patie
Externí odkaz:
https://doaj.org/article/38097a3f4f084b048ee5945faefafe29
Autor:
Romualdo Barroso-Sousa, Rodrigo R. Munhoz, Milena P. Mak, Leonardo G. Fonseca, Angelo B. S. Fede, Rudinei Diogo Marques Linck, Clovis R. Coelho, Camila M. V. Moniz, Ciro E. Souza, Carlos Dzik
Publikováno v:
International Brazilian Journal of Urology, Vol 40, Iss 6, Pp 835-841 (2014)
Purpose To assess the activity, safety and treatment patterns of sunitinib in patients with poor-risk metastatic renal cell carcinoma (mRCC). Materials and Methods We retrospectively reviewed the charts of poor risk patients treated with sunitinib fr
Externí odkaz:
https://doaj.org/article/375918afa0b04176931af29148506301
Autor:
Natalia M. P. Fraile, Diego Toloi, Ceci O. Kurimori, Adriana R. B. Matutino, Alberto Codima, Veridiana P. Camargo, Olavo Feher, Rodrigo R. Munhoz
Publikováno v:
Case Reports in Oncological Medicine, Vol 2015 (2015)
Giant cell tumor of bone (GCT) is a rare, locally aggressive neoplasm characterized by the presence of giant cells with osteoclast activity. Its biology involves the overexpression of the Receptor Activator of Nuclear Factor kB Ligand (RANKL) by oste
Externí odkaz:
https://doaj.org/article/387c0fc7b0a9440db4494680f19a31f3
Autor:
Marcello M. Queiroz, Rodrigo R. Munhoz, Cibele Masotti, Larissa M. Souza, Luiz G.C.A. Lima, Paula F. Asprino, Maria Dirlei F.S. Begnami, Anamaria A. Camargo, Fabiana Bettoni
Publikováno v:
JCO precision oncology. 6
Autor:
Rodrigo R. Munhoz, Guilherme Nader‐Marta, Veridiana P. de Camargo, Marcello M. Queiroz, Jade Cury‐Martins, Hermínia Ricci, Marcela R. de Mattos, Thiago A. F. de Menezes, Guilherme U. C. Machado, Eduardo Bertolli, Milton Barros, Carina E. de Souza, Fábio Franke, Fabio O. Ferreira, Olavo Feher, Gilberto de Castro
Publikováno v:
CancerREFERENCES. 128(24)
Cutaneous squamous-cell carcinoma (CSCC) is among the most frequent malignancies worldwide. For those not amenable to treatment with curative intent, immune checkpoint inhibition (ICI) with anti-programmed death receptor 1 (PD-1) antibodies has emerg
Autor:
Alain P, Algazi, Katy K, Tsai, Alexander N, Shoushtari, Rodrigo R, Munhoz, Zeynep, Eroglu, Josep M, Piulats, Patrick A, Ott, Douglas B, Johnson, Jimmy, Hwang, Adil I, Daud, Jeffrey A, Sosman, Richard D, Carvajal, Bartosz, Chmielowski, Michael A, Postow, Jeffrey S, Weber, Ryan J, Sullivan
Publikováno v:
Cancer, vol 122, iss 21
BackgroundAntibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::33b16b17b8c9b9d16449d33a5a14f3cd
https://europepmc.org/articles/PMC5767160/
https://europepmc.org/articles/PMC5767160/
Autor:
Munhoz R; Oncology Center, Hospital Sírio Libanês, São Paulo, Brazil., Sabesan S; Townsville Cancer Centre, Townsville Hospital and Health Services, Townsville, Queensland, Australia., Thota R; Intermountain Health, Salt Lake City, UT., Merrill J; American Society of Clinical Oncology, Alexandria, VA., Hensold JO; Bozeman Health, Bozeman, MT.
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting [Am Soc Clin Oncol Educ Book] 2024 Jun; Vol. 44 (3), pp. e432078.